EU JCA Dossier Development & Assessment Support
Transform Evidence into a High-Quality EU JCA Submission
Develop robust, compliant and fit-for-purpose EU JCA dossiers. Our integrated approach combines scientific expertise, advanced analytics, and medical writing excellence to deliver submission-ready dossiers that stand up to scrutiny.
A strong EU JCA dossier is more than a collection of evidence summaries. It is the documented expression of the sponsor’s evidence strategy: what evidence was considered, why particular studies and methods were selected, how analyses were conducted and where uncertainty remains.
Cytel combines scientific writing with evidence synthesis, comparative effectiveness and statistical expertise to build dossiers that are coherent, transparent, and aligned with EU JCA requirements.
Talk to an EU JCA expertBring the Evidence Story Together
The JCA dossier brings together evidence generated across multiple workstreams. Clinical trial evidence, systematic reviews, supplementary evidence, comparative analyses, and methodological decisions need to tell one consistent story.
Cytel’s dossier teams work across those dependencies rather than treating writing as an isolated activity. We align dossier content with the underlying evidence, ensure the methods are described consistently and create a clear rationale for decisions that assessors will need to understand.
A Dossier Built for Scrutiny
The JCA dossier places significant emphasis on transparent reporting of evidence identification, study selection, analytical methods, subgroup and sensitivity analyses, and methodological justification.
Cytel’s approach is therefore built around scientific and quality review at every stage. We can review existing SLR and ITC outputs for compatibility with JCA requirements, integrate evidence generated by multiple vendors, coordinate cross-functional review and conduct detailed QC of data, numbers and references. The objective is to produce a dossier that is not only complete, but internally consistent and defensible.
Manage the Changing Scope
The final assessment scope can require important updates to material prepared earlier in the programme. This is why dossier development needs to be treated as a dynamic process rather than a single writing cycle.
Cytel can establish a living JCA analysis plan and evidence map so that changes to the PICO scope, evidence base, clinical landscape or analytical strategy can be incorporated systematically. This approach helps sponsors avoid losing the connection between early evidence planning and the final submitted dossier.
Post-Submission Support
The end of dossier submission is not necessarily the end of the work.
Cytel can support the sponsor through completeness checks and subsequent assessor requests, coordinating the required inputs across evidence synthesis, ITC, statistics, dossier, and internal sponsor teams.
Where additional data, analyses or explanations are requested, we help determine the appropriate response strategy and ensure that the response remains consistent with the submitted evidence and methodology.
FAQs
Can Cytel develop a dossier if another vendor conducted the SLR or ITC?
Yes. Cytel can integrate externally generated evidence, but the material needs to be reviewed against JCA methods and reporting requirements.
Does Cytel provide post-submission support?
Yes. Support can include completeness checks, assessor-response strategy, coordination of inputs and development or updating of analyses and evidence where requested.
Why is scientific QC important?
Because errors or inconsistencies between evidence-generation outputs and the dossier can undermine credibility and create additional work under already compressed timelines.
We help sponsors prepare for JCAs
Preparing for an upcoming EU JCA? Talk to Cytel’s experts about building an integrated evidence strategy.